首页> 外文期刊>Current hypertension reports. >Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation.
【24h】

Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation.

机译:丙二酰辅酶A脱羧酶是心肌脂肪酸氧化的主要调节剂。

获取原文
获取原文并翻译 | 示例
           

摘要

The energy demands of the heart are normally met by oxidation of both glucose and fatty acids. Fatty acid oxidation is limited by the uptake of fatty acyl coenzyme A (CoA) into the mitochondria, a process regulated by carnitine palmitoyltransferase (CPT)1. Malonyl CoA is a potent endogenous inhibitor of CPT1, and therefore plays an integral role in the control of myocardial fatty acid oxidation. Malonyl-CoA decarboxylase (MCD) is responsible for the removal of malonyl CoA and may control myocardial fatty acid oxidation. Indeed, strategies using MCD inhibitors and MCD knockout mice have provided the first evidence for a direct role of MCD in the control of myocardial fatty acid oxidation. Based on these studies, pharmacologic inhibition of MCD has been proposed to be a viable approach for the treatment of ischemic heart disease resulting from a variety of pathologic conditions, including coronary artery diseases, pathologic hypertrophy, and hypertension.
机译:葡萄糖和脂肪酸的氧化通常可以满足心脏的能量需求。脂肪酸氧化受到脂肪酰基辅酶A(CoA)进入线粒体的限制,线粒体是肉碱棕榈酰转移酶(CPT)1调节的过程。丙二酰辅酶A是有效的内源性CPT1抑制剂,因此在控制心肌脂肪酸氧化中起着不可或缺的作用。丙二酰辅酶A脱羧酶(MCD)负责丙二酰辅酶A的去除,并且可以控制心肌脂肪酸的氧化。实际上,使用MCD抑制剂和MCD基因敲除小鼠的策略已提供了MCD在控制心肌脂肪酸氧化中直接作用的第一个证据。基于这些研究,已提出MCD的药理抑制作用是治疗由多种病理状况(包括冠状动脉疾病,病理性肥大和高血压)引起的缺血性心脏病的可行方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号